Quarterly ResultJun 11, 2026, 08:01 AM
Rafael Holdings Reports Q3 Loss of $4.2M; Completes Phase 3 Trial Enrollment
AI Summary
Rafael Holdings, Inc. announced its financial results for the third quarter ended April 30, 2026. The company reported a net loss of $4.2 million, or $0.08 per share, compared to a net loss of $4.8 million, or $0.19 per share, in the prior year period. Research and development expenses increased due to the consolidation of Cyclo Therapeutic's expenses following an acquisition. The company also announced the completion of the last patient last visit for its pivotal Phase 3 TransportNPC™ trial and expects to submit an NDA in the second half of calendar 2026.
Key Highlights
- Rafael Holdings reports Q3 FY2026 net loss of $4.2M ($0.08/share) vs $4.8M ($0.19/share) YoY.
- Q3 FY2026 R&D expenses increased to $4.9M from $3.0M YoY due to Cyclo consolidation.
- Q3 FY2026 G&A expenses decreased to $2.1M from $3.2M YoY.
- Company had $30.5M in cash and cash equivalents as of April 30, 2026.
- Nine months FY2026 net loss was $20.5M ($0.40/share) vs $18.4M ($0.73/share) YoY.
- Completed last patient last visit for pivotal Phase 3 TransportNPC™ trial.
- Expects to submit NDA in the second half of calendar 2026.
Price Impact
More from RFL